Citadel Advisors’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-540
| Closed | -$5.7K | – | 13852 |
|
|
2026
Q1 | $6.12K | Sell |
540
-6,924
| -93% | -$94.5K | ﹤0.01% | 12803 |
|
|
2025
Q4 | $95.4K | Buy |
7,464
+4,179
| +127% | +$64.3K | ﹤0.01% | 11681 |
|
|
2025
Q3 | $61.4K | Buy |
+3,285
| New | +$64.7K | ﹤0.01% | 12092 |
|
|
2025
Q2 | – | Sell |
-409
| Closed | -$8.21K | – | 12909 |
|
|
2025
Q1 | $8.18K | Buy |
+409
| New | +$8.62K | ﹤0.01% | 13653 |
|
|
2024
Q4 | – | Sell |
-1,454
| Closed | -$28.5K | – | 14638 |
|
|
2024
Q3 | $43.6K | Buy |
+1,454
| New | +$31.9K | ﹤0.01% | 12059 |
|
|
2023
Q4 | – | Sell |
-1,534
| Closed | -$57.7K | – | 14383 |
|
|
2023
Q3 | $57.7K | Sell |
1,534
-356
| -19% | -$20.4K | ﹤0.01% | 11582 |
|
|
2023
Q2 | $136K | Buy |
1,890
+1,230
| +186% | +$77.8K | ﹤0.01% | 10480 |
|
|
2023
Q1 | $44.5K | Buy |
+660
| New | +$39.6K | ﹤0.01% | 12312 |
|
|
2022
Q3 | – | Sell |
-6,345
| Closed | -$278K | – | 12757 |
|
|
2022
Q2 | $278K | Buy |
6,345
+5,215
| +462% | +$239K | ﹤0.01% | 9963 |
|
|
2022
Q1 | $73K | Buy |
1,130
+89
| +9% | +$6.38K | ﹤0.01% | 12544 |
|
|
2021
Q4 | $87K | Sell |
1,041
-2,037
| -66% | -$229K | ﹤0.01% | 12844 |
|
|
2021
Q3 | $500K | Buy |
3,078
+1,507
| +96% | +$245K | ﹤0.01% | 9863 |
|
|
2021
Q2 | $237K | Buy |
1,571
+389
| +33% | +$65.6K | ﹤0.01% | 11798 |
|
|
2021
Q1 | $205K | Sell |
1,182
-2,278
| -66% | -$434K | ﹤0.01% | 11643 |
|
|
2020
Q4 | $552K | Sell |
3,460
-3,030
| -47% | -$507K | ﹤0.01% | 7951 |
|
|
2020
Q3 | $1.04M | Buy |
6,490
+1,708
| +36% | +$308K | ﹤0.01% | 5967 |
|
|
2020
Q2 | $947K | Buy |
4,782
+4,260
| +816% | +$782K | ﹤0.01% | 5933 |
|
|
2020
Q1 | $81K | Sell |
522
-861
| -62% | -$86.9K | ﹤0.01% | 8771 |
|
|
2019
Q4 | $106K | Buy |
+1,383
| New | +$121K | ﹤0.01% | 8523 |
|
|
2019
Q2 | – | Sell |
-802
| Closed | -$121K | – | 9253 |
|
|
2019
Q1 | $121K | Buy |
+802
| New | +$125K | ﹤0.01% | 8482 |
|
|
2018
Q2 | – | Sell |
-565
| Closed | -$107K | – | 8874 |
|
|
2018
Q1 | $80K | Buy |
+565
| New | +$85.4K | ﹤0.01% | 7787 |
|
|
2016
Q4 | – | Sell |
-826
| Closed | -$106K | – | 7318 |
|
|
2016
Q3 | $106K | Buy |
+826
| New | +$85.9K | ﹤0.01% | 6631 |
|
|
2015
Q4 | – | Sell |
-423
| Closed | -$53K | – | 8775 |
|
|
2015
Q3 | $53K | Sell |
423
-92
| -18% | -$12.3K | ﹤0.01% | 7538 |
|
|
2015
Q2 | $63K | Buy |
+515
| New | +$70.1K | ﹤0.01% | 7495 |
|
Other funds holding CTSO
CM
Citadel Advisors's CTSO Position: Q2 2026 in Review
Citadel Advisors sold out of Cytosorbents Corp (CTSO) in Q2 2026, closing a stake of 540 shares — an estimated $5.7K sold.
Citadel Advisors first reported a position in CTSO in Q2 2015 and held it in 24 quarters. The position peaked at $1.04M in Q3 2020. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Citadel Advisors reported no remaining Cytosorbents Corp position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 540 Cytosorbents Corp shares in Q2 2026, an estimated $5.7K.
- Citadel Advisors first reported a position in Cytosorbents Corp in Q2 2015 and held it in 24 quarters.
- Citadel Advisors's Cytosorbents Corp position peaked at $1.04M in Q3 2020.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.